Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-1656. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK known ✓ | P35557 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-1656 SCHEMBL1427162 | 1.00 | GCK (1.00) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| Azd-1656 SCHEMBL30292634 | 1.00 | GCK (1.00) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| Azd-1656 SCHEMBL20299733 | 1.00 | GCK (1.00) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| Azd-1656 SCHEMBL29358604 | 1.00 | GCK (1.00) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL2661628 | 0.92 | GCK (0.85) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1426451 | 0.92 | GCK (0.85) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL2587617 | 0.92 | GCK (0.84) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| Water SCHEMBL2592088 | 0.91 | GCK (0.84) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1427170 | 0.90 | GCK (0.82) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1427085 | 0.90 | GCK (0.81) | GCKKCNH2CYP1A2ABCB1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282763-A1 | THERAPEUTIC COCRYSTALS OF 3-{[5-(AZETIDINE-1-YLCARBONYL)PYRAZIN-2-YL]OXY}-5-{[(1S)-1-METHYL-2-(METHYLOXY)ETHYL]OXY)-N-(5-METHYLPYRAZIN-2-YL)BENZAMIDE | CONDUIT UK MANAGEMENT LTD (GB) | 2025-09-11 | — | — | US | claimed |
| US-20230128372-A1 | AZD1656 FOR USE IN THE TREATMENT OF PNEUMONITIS AND/OR MYCORDITIS CAUSED BY A CORONAVIRUS | EXCALIBUR MEDICINES LIMITED (GB) | 2023-04-27 | — | — | US | claimed |
| US-20200188394-A1 | TREATMENT OF LIVER DISEASE | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2020-06-18 | — | — | US | claimed |
| EP-3558375-A1 | TREATMENT OF LIVER DISEASE | University of Newcastle Upon Tyne (GB) | 2019-10-30 | — | — | EP | claimed |
| WO-2018115845-A1 | TREATMENT OF LIVER DISEASE | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2018-06-28 | — | — | WO | claimed |
| EP-1902052-B1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2012-11-28 | — | — | EP | claimed |
| EP-2396317-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | claimed |
| US-8076481-B2 | Chemical process 632 | ASTRAZENECA AB (SE) | 2011-12-13 | — | — | US | claimed |
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | claimed |
| EP-2305674-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | claimed |
| WO-2010092386-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | claimed |
| US-7642259-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | claimed |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| US-20250282763-A1 | THERAPEUTIC COCRYSTALS OF 3-{[5-(AZETIDINE-1-YLCARBONYL)PYRAZIN-2-YL]OXY}-5-{[(1S)-1-METHYL-2-(METHYLOXY)ETHYL]OXY)-N-(5-METHYLPYRAZIN-2-YL)BENZAMIDE | CONDUIT UK MANAGEMENT LTD (GB) | 2025-09-11 | — | — | US | disclosed |
| US-20250282763-A1 | THERAPEUTIC COCRYSTALS OF 3-{[5-(AZETIDINE-1-YLCARBONYL)PYRAZIN-2-YL]OXY}-5-{[(1S)-1-METHYL-2-(METHYLOXY)ETHYL]OXY)-N-(5-METHYLPYRAZIN-2-YL)BENZAMIDE | CONDUIT UK MANAGEMENT LTD (GB) | 2025-09-11 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | GCK 1/4885KCNH2 1128/4885CYP1A2 51/4885 |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | GCK 1/4885KCNH2 993/4885CYP1A2 83/4885 |
| US-20250282763-A1 | THERAPEUTIC COCRYSTALS OF 3-{[5-(AZETIDINE-1-YLCARBONYL)PYRAZIN-2-YL]OXY}-5-{[(1S)-1-METHYL-2-(METHYLOXY)ETHYL]OXY)-N-(5-METHYLPYRAZIN-2-YL)BENZAMIDE | CA6, IDH1, FH | GCK 214/4885KCNH2 1416/4885CYP1A2 2074/4885 |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | GCKR, GCK, HK1 | GCK 2/4885KCNH2 631/4885CYP1A2 1358/4885 |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | GCK 1/4885KCNH2 993/4885CYP1A2 83/4885 |
| US-20230128372-A1 | AZD1656 FOR USE IN THE TREATMENT OF PNEUMONITIS AND/OR MYCORDITIS CAUSED BY A CORONAVIRUS | PIM1, MYC, PIM3 | GCK 1621/4885KCNH2 539/4885CYP1A2 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.